IP Library Granted Patent US 12667602
Granted Patent B2
US 12667602 · App. 17/625,437 · Granted Jun 30, 2026

Composition for preventing, treating or alleviating diabetes, comprising LGI3-derived peptide as an active ingredient

Inventors: Hye-Young Yun (Seoul, KR); Dong-Seok Kim (Seoul, KR)
Assignee: CHUNG-ANG UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
A61K38/1709A61K38/10A61P1/16A61P1/18A61P3/00A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12667602
App. No.
17/625,437
Granted
Jun 30, 2026
Kind
B2
Abstract

The present invention relates to a composition and the like, for preventing, treating or alleviating diabetes, comprising an LGI3-derived peptide as an effective component. The composition comprising, as an active ingredient, an LGI3-derived peptide comprising an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 of the present invention exhibits an inhibitory effect on weight gain, elevation of blood glucose levels, pancreas and liver damage, elevation of blood lipid levels, and an increase of insulin resistance indexes accompanied by diabetes and diabetes-associated metabolic disorders associated with diabetes, and thus can prevent, treat, or alleviate diabetes and metabolic disorders associated with diabetes.

Claims (4)

1 . A method of treating pancreatic exocrine insufficiency generated in diabetes in a subject comprising:

administering a pharmaceutically effective amount of a composition comprising a leucine-rich repeat LGI family member 3 (LGI3)-derived peptide comprising an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an active ingredient into the subject, and

wherein the LGI3-derived peptide increases zymogen granules of the pancreas and pancreatic weight, and reduces a blood sugar level.

2 . A method of treating a diabetes-associated metabolic disorder in a subject by administering a pharmaceutical composition comprising an effective amount a leucine-rich repeat LGI family member 3 (LGI3)-derived peptide comprising an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an active ingredient into the subject wherein the diabetes-associated metabolic disorder is one or more selected from the group consisting of hyperglycemia, liver damage associated with an elevated aspartate aminotransferase (AST) level, and pancreatic damage.